4.7 Article

Chronic immune response dysregulation in MDS pathogenesis

期刊

BLOOD
卷 132, 期 15, 页码 1553-1560

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2018-03-784116

关键词

-

资金

  1. Cincinnati Children's Hospital Research Foundation
  2. Leukemia and Lymphoma Society
  3. National Institutes of Health, National Heart, Lung, and Blood Institute [R35HL135787, F32HL143993]
  4. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases [RO1DK113639, RO1DK102759]
  5. American Society of Hematology
  6. National Institutes of Health, National Institute of Environmental Health Sciences [T32ES007250]
  7. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL143993, R35HL135787] Funding Source: NIH RePORTER
  8. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK113639, R01DK102759] Funding Source: NIH RePORTER
  9. NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Chronic innate immune signaling in hematopoietic cells is widely described in myelodysplastic syndromes (MDS), and innate immune pathway activation, predominantly via pattern recognition receptors, increases the risk of developing MDS. An inflammatory component to MDS has been reported for many years, but only recently has evidence supported a more direct role of chronic innate immune signaling and associated inflammatory pathways in the pathogenesis of MDS. Here we review recent findings and discuss relevant questions related to chronic immune response dysregulation in MDS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据